上海
在藥明康德，我們始終相信：所有的進步，都源于交流與合作。
25年來，從第一位客戶起步，我們以合作的力量賦能整個生物醫藥產業，幫助更多創新療法更快來到全球患者身邊。
如今，在藥明康德一體化的CRDMO平臺上，來自全球三十多個國家、數千家合作伙伴的研發項目正同步進行。
研發、生產、交付——彼此銜接，默契如樂團的合奏：有人奏響主旋律，有人織就和聲。每一次協作，最終都匯成生命的樂章。
在音樂之都維也納，在本周歐洲生物技術大會（BIO-Europe）期間，近300名產業資深人士齊聚“藥明之夜”，共同聆聽合作帶來的和聲與共鳴。
助力每一個科學創新
維也納，這座成就了莫扎特與貝多芬的城市，如今正譜寫新的旋律。
過去三十年間，它已成長為歐洲最具活力的生命科學中心之一——
700多家生命科學機構匯聚于此，每年吸引逾40億歐元投資，勃林格殷格翰、武田等全球藥企深耕布局。
繁榮之下，挑戰仍在。行業媒體
BioXconomy，盡管歐洲科研成果不斷涌現，但創新轉化依舊艱難，尤其對初創公司而言。
而藥明康德這樣的CRDMO平臺，正以靈活、可靠的體系，幫助每一個創新想法從實驗室走向患者。
“科學的進步，正在重新定義疾病的治療。”
藥明康德聯席首席執行官楊青博士在致辭中表示。
“從不可成藥的靶點到復雜的新分子療法，藥明康德將立足全球布局，不斷‘建能力、擴規模’，以科學家的嚴謹與端到端的賦能體系，助力客戶加速創新。”
正如樂曲雖千變萬化，仍回歸熟悉的旋律——
始終專注為客戶提供高質量服務，是藥明康德不變的主題。
“合作伙伴是成功的加速器”
“我們的產業正在回暖。”
德國默克風投（M Ventures）董事總經理、生物技術投資負責人Hakan Goker博士在藥明之夜上說道。他指出，今年每個季度的投融資表現都優于去年。
作為一家管理6億歐元的風投機構，德國默克風投已投資逾百家公司，其中許多專注于攻克最具挑戰性的疾病。
“初創公司要想走得遠，必須目標清晰，也要無懼風雨、砥礪前行。”他說。
幾個月前剛完成6500萬美元A輪融資的ReproNovo公司，則從創業者角度分享了合作和堅持的力量。
ReproNovo花了三年時間構建核心管線，最終憑借與投資人和生態圈的長期協作，讓兩款候選療法順利進入臨床。
“沒有合作，一切都無從談起。”首席執行官Jean Marie Duvall女士回顧說。
她也坦言，這段歷程并非輕而易舉，離不開團隊不斷堅持下去的信念。
有著20多年投資經驗的Karl Naegler博士（Sofinnova合伙人）則強調了速度的重要性。“速度與執行力本身就是戰略。”他說。
在拜訪藥明康德時，他深刻體會到高效協作如何推動研發前進。
“新藥研發歷來風險高、周期長，但更快意味著更多嘗試與迭代，也意味著更高的成功率與更低的成本。
“找到值得信賴、擁有同樣思維模式與技術實力的伙伴，就是成功的加速器。”
Sofinnova今年宣布新籌集12億歐元，助力下一波生命科學創新浪潮。Naegler博士專注歐洲投資并在德國擁有豐富經驗，也將通過扶持初創公司推動德國乃至歐洲的科學成果轉化落地。
他還提到，像“藥明之夜”這樣的產業交流活動正成為各大會議的常態，并期待這類對話持續激發創新合作的新活力。
向未來，懷抱信念
藥明康德副總裁蔡輝博士總結，現場生態圈領袖的分享，傳遞出三個關鍵詞。
樂觀：全球患者對好藥新藥的需求從未改變。冬去春來，創新的種子正在發芽。
韌性：無論面對怎樣的市場起伏，堅持、勇氣與信念，才能讓創新穿越風浪。
長期主義：經濟有周期，但只要始終“做對的事，把事做好”，終將迎來更好的未來。
這三個詞，也正是藥明康德25年來的寫照。
從一間實驗室到橫跨亞洲、北美和歐洲的全球網絡，從化學合成到一體化CRDMO平臺——
不斷增長的是能力與規模，不變的是夢想與承諾。
我們堅信，每一次握手、每一場討論、每一個合作，都在加速創新療法的誕生，讓更多患者從科學進步中受益。
“讓天下沒有難做的藥，難治的病”。這不僅是愿景，更是前行的方向。
In Vienna, WuXi AppTec Strikes a New Chord of Innovation
At WuXi AppTec, we have always believed thatevery breakthrough begins with conversations and connections.
For 25 years, from our very first client onward, we have empowered the global biopharmaceutical industry through partnership, helping more innovative therapies reach patients faster around the world.
Today, on WuXi AppTec’s integrated CRDMO platform, R&D projects from over 30 countries and thousands of partners are progressing in harmony.
From research to manufacturing to delivery, every step connects seamlessly, like instruments in an orchestra: some carry the melody, others enrich the harmony.
Together, they compose a symphony of life.
In Vienna, the City of Music, alongside this week’s BIO-Europe conference, our “WuXi Night” attracted around 300 guests and once again resonated with the sound of collaboration and shared vision.
Enabling Every Scientific Innovation
Vienna, the city that gave rise to Mozart and Beethoven, is composing a new melody today.
Over the past 30 years, it has become one of Europe’s most dynamic life science hubs—
home to more than 700 institutions, attracting over €4 billion in annual investment, and hosting global leaders such as Boehringer Ingelheim and Takeda.
Yet beneath the prosperity, challenges remain.
As industry media
BioXconomynoted, while European research continues to thrive, translating innovation into therapies remains difficult, especially for small startups.
CRDMO platforms like WuXi AppTec are changing that landscape, providing flexible and reliable solutions that help every great idea move from the lab to the patient.
“Scientific progress is transforming how diseases are treated,” said Dr. Steve Yang, Co-CEO of WuXi AppTec, in his remarks.
“From once ‘undruggable’ targets to complex new modalities, WuXi AppTec will continue to expand capabilities and capacity worldwide, supporting our clients’ innovation journeys with scientific rigor and an integrated, end-to-end enabling platform.”
Just as every piece of music ultimately returns to its familiar motif, WuXi AppTec’s constant refrain is its unwavering commitment to quality and service.
“Partners Are Accelerators of Success”
“Our industry is recovering,” said Dr. Hakan Goker, Managing Director of M Ventures, who also heads Biotechnology Investments, during WuXi Night.
He noted that fundraising has improved every quarter this year compared to last.
Managing a €600 million portfolio and over 100 investments, many focused on treating the world’s most challenging diseases, Dr. Goker emphasized:
“Startups that aim to go far must have clear goals and forge ahead undaunted.”
ReproNovo, which recently completed a $65 million Series A round, shared the entrepreneur’s perspective on collaboration and unwavering grit.
The company spent three years building its core pipeline and, through continuous engagement with investors and ecosystem partners, successfully advanced two lead candidates into clinical trials.
“Nothing happens without collaboration,” said CEO Jean Marie Duvall, reflecting on the journey.
She also noted that this did not happen overnight, and the team’s persistence and determination were key to advancing their goals.
With more than 20 years of investment experience, Dr. Karl Naegler, Partner at Sofinnova, highlighted another essential factor: speed.
“Speed and execution are the strategy,” he said.
During a recent visit to WuXi AppTec, he was struck by how efficiency and teamwork can accelerate R&D.
“Drug development has always been risky and time-consuming,” he noted, “but moving faster means more iteration, higher success rates, and lower costs. Finding a trustworthy partner with the right mindset and technical strength is the true accelerator of success.”
Sofinnova announced a €1.2 billion fund this year to fuel the next wave of life sciences innovation. Dr. Naegler, with deep experience in Germany, will further support startups to translate scientific breakthroughs in Germany and across Europe.
He also noted that industry networking events like “WuXi Night” are becoming a staple at major conferences, and he hopes such dialogues will continue to spark new collaboration and innovation.
Looking Ahead with Confidence
At the event, Dr. Hui Cai, Vice President of WuXi AppTec, summarized the insights shared by ecosystem leaders around three keywords:
Optimism— The global demand for better medicines never fades. Winter is ending, and the seeds of innovation are beginning to bloom.
Resilience— Whether on stage or in the audience, every leader spoke of resilience, the courage and conviction to stay the course through every storm.
Long-term Vision— The economy moves in cycles, but those who “do the right thing, and do it right” will always emerge stronger.
These three words also capture the spirit of WuXi AppTec’s 25-year journey.
From a single laboratory to a global network across Asia, Europe, and North America; from chemistry services to a fully integrated CRDMO platform, our scale and capability continue to grow, while our mission and commitment remain steadfast.
We believe that every handshake, every discussion, and every collaboration brings the world closer to breakthrough therapies and to a brighter, healthier future.
“Every drug can be made and every disease can be treated.”
This is not only our vision; it is the direction that keeps us moving forward.
免責聲明：本文 僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療 方案指導，請前往正規醫院就診。
版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。
特別聲明：以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布，本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
